LPGO.ST实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 23:15):

Stats
今日成交量	614 831
平均成交量	538 035
市值	45.45M
EPS	SEK0 ( 2024-02-22 )
下一个收益日期	( SEK0 ) 2024-05-24
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-1.890
ATR14	SEK0.00900 (2.50%)

音量相关性

長: -0.06 (neutral)

短: -0.59 (weak negative)

Signal:(58.156) Neutral

Lipigon Pharmaceuticals 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Lipigon Pharmaceuticals 相关性 - 货币/商品

0.14
( neutral )

0.08
( neutral )

0.00
( neutral )

-0.09
( neutral )

Lipigon Pharmaceuticals 财务报表

Annual	2023
营收:	SEK16.41M
毛利润:	SEK-12.58M (-76.66 %)
EPS:	SEK-0.190

FY	2023
营收:	SEK16.41M
毛利润:	SEK-12.58M (-76.66 %)
EPS:	SEK-0.190

FY	2022
营收:	SEK390 000
毛利润:	SEK366 000 (93.85 %)
EPS:	SEK-2.12

FY	2021
营收:	SEK3.18M
毛利润:	SEK0.00 (0.00 %)
EPS:	SEK-4.56

Financial Reports:

No articles found.

Lipigon Pharmaceuticals

Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease and familial chylomicronemia syndrome; a gene therapy project for the lipodystrophy, a rare disease of altered fat distribution in the body; therapeutics for dyslipidemia, a general lipid disorder; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia, cardiovascular disease, and other metabolic diseases. The company was founded in 2010 and is based in Umeå, Sweden.